What is dacryocystitis? Symptoms, causes & treatment

Dacryocystitis is infection and inflammation of the lacrimal sac, almost always secondary to nasolacrimal duct obstruction that causes tear stasis and bacterial overgrowth. It presents with acute pain, erythema, and swelling at the medial canthus with mucopurulent discharge and tearing. Diagnosis is clinical; expressed purulence from the punctum is characteristic. Treatment is systemic antibiotics, warm compresses, and, after the acute episode resolves, definitive drainage surgery (dacryocystorhinostomy) if obstruction persists.

Key Points

• Dacryocystitis is infection of the lacrimal sac, typically due to downstream nasolacrimal duct obstruction and tear stasis.
• Acute cases require systemic antibiotics; topical drops are adjuncts and are not sufficient as monotherapy.
• Recurrent or chronic dacryocystitis is cured in most patients by dacryocystorhinostomy (external or endoscopic).
• Neonatal/infant dacryocystitis can progress to sepsis; low threshold for hospital admission and IV antibiotics.
• Complications include lacrimal sac abscess, preseptal/orbital cellulitis, fistula, and rarely cavernous sinus thrombosis or meningitis.
• Consider MRSA risk, atypical organisms, and lacrimal sac tumors when presentations are severe, recurrent, or atypical.

Anatomy and Physiology

The lacrimal drainage system begins at the upper and lower puncta on the eyelid margins, continues through the canaliculi (often joining into a common canaliculus), and enters the lacrimal sac located in the lacrimal fossa at the medial canthus. The nasolacrimal duct (NLD) exits the sac and drains into the inferior nasal meatus. One-way mucosal folds (valve of Rosenmüller at the sac–canaliculus junction and valve of Hasner at the NLD–nasal opening) regulate tear flow. Obstruction anywhere distal to the sac promotes tear stasis and infection in the sac.

Etiology

• Obstruction-related
  • Primary acquired nasolacrimal duct obstruction (PANDO), often idiopathic, fibrosis-related
  • Secondary acquired obstruction: chronic rhinosinusitis, trauma (including nasal fractures), nasal or sinus surgery, medications (e.g., topical timolol or pilocarpine associated with canalicular stenosis), granulomatous disease (sarcoidosis, granulomatosis with polyangiitis), irradiation, neoplasms
• Congenital nasolacrimal duct obstruction (CNLDO): failure of canalization at the valve of Hasner
• Pathogens (typical)
  • Gram-positive: Staphylococcus aureus (including MRSA), coagulase-negative staphylococci, Streptococcus pneumoniae, beta-hemolytic streptococci
  • Gram-negative: Haemophilus influenzae, Pseudomonas aeruginosa (especially in chronic/healthcare exposures)
  • Anaerobes and Actinomyces species in chronic canalicular/saccal disease
  • Fungal organisms (e.g., Candida) in immunocompromised hosts

Pathophysiology

Obstruction distal to the lacrimal sac raises intraluminal pressure and causes tear stasis, epithelial injury, and loss of normal antimicrobial tear defenses. Stasis allows colonization by skin and respiratory flora. Inflammation and edema further narrow the lumen, creating a cycle of obstruction and infection. Acute dacryocystitis features neutrophilic inflammation and may form a localized abscess; chronic disease features mucosal hyperplasia, granulation tissue, dacryoliths (concretions), and low-grade infection.

Epidemiology

• More common in females and in older adults, reflecting higher rates of acquired nasolacrimal duct obstruction [1,2].
• Congenital nasolacrimal duct obstruction occurs in approximately 5% of newborns, with most resolving spontaneously by 6 to 12 months; true neonatal dacryocystitis is uncommon but can be severe [3].
• Laterality is usually unilateral. Bilateral involvement warrants evaluation for systemic or sinonasal causes.

Classification

• By time course
  • Acute dacryocystitis
  • Chronic dacryocystitis
• By age/etiology
  • Congenital (CNLDO with superinfection; dacryocele/dacryocystocele)
  • Acquired (primary or secondary obstruction)
• By complications
  • Uncomplicated vs complicated (abscess, preseptal/orbital cellulitis, fistula)

Symptoms and Signs

• Acute dacryocystitis (adults)

  • Sudden-onset pain, erythema, warmth, and tender swelling over the lacrimal sac (medial canthus)
  • Epiphora (tearing), mucopurulent discharge; pressure on the sac may express pus from the punctum
  • Fever and malaise in more severe infections
  • Fluctuance indicates abscess; overlying skin may thin or point

• Chronic dacryocystitis

  • Longstanding tearing with intermittent mucous discharge
  • Non-tender medial canthal fullness; pressure produces mucopurulent reflux
  • Recurrent conjunctivitis and blepharitis

• Infants and children

  • CNLDO: tearing and mucous crusting from birth
  • Acute infection: irritability, fever, erythematous tender medial canthal swelling; risk of preseptal/orbital cellulitis and sepsis
  • Dacryocele: bluish, cystic medial canthal mass; intranasal component can obstruct the airway in neonates

Red-flag findings suggesting extension or alternative diagnoses: decreased vision, ophthalmoplegia or pain with eye movements, proptosis, severe headache, high fever, bloody reflux, firm non-tender mass persisting between infections.

Complications

• Preseptal cellulitis; orbital cellulitis
• Lacrimal sac abscess and cutaneous fistula
• Sepsis (especially neonates), meningitis, cavernous sinus thrombosis (rare)
• Corneal exposure or keratitis from severe lid edema
• Endophthalmitis risk if intraocular surgery is performed in the setting of active infection

Diagnosis

Clinical evaluation

• Diagnosis is clinical in typical cases: focal tenderness and erythema over the lacrimal sac, epiphora, and mucopurulent reflux from the punctum with gentle pressure.
• Do not forcibly massage in severe acute infection; minimal pressure can obtain a culture.
• Assess visual acuity, pupils, extraocular movements, proptosis, and pain with eye movements to exclude orbital cellulitis.

Imaging and laboratory testing

• Gram stain and culture of expressed purulence or abscess contents guide therapy in severe, recurrent, hospital-acquired, or immunocompromised cases.
• Blood cultures in neonates, febrile/toxic patients, or those with systemic involvement.
• CT orbits and sinuses with contrast if orbital cellulitis is suspected, if there is poor response to therapy, or to evaluate for neoplasm or sinonasal pathology.
• Nasal endoscopy (ENT) when secondary causes are suspected or for surgical planning.

Differential diagnosis

Treatment

Acute dacryocystitis is a soft-tissue infection of the lacrimal sac; systemic antibiotics are required. Topical antibiotics are adjunctive for conjunctival discharge but are inadequate alone.

Medical management

• Adults, uncomplicated outpatient therapy (empiric; adjust per culture)
  • amoxicillin-clavulanate 875/125 mg PO bid (every 12 hours) for 7–10 days [1,4]
  • cephalexin 500 mg PO q6h (every 6 hours) for 7–10 days [1]
  • If MRSA risk or beta-lactam allergy:
  • clindamycin 300 mg PO q6–8h for 7–10 days (covers MRSA and streptococci) [4]
  • trimethoprim-sulfamethoxazole (DS) 1 tab PO bid plus amoxicillin-clavulanate 500/125 mg PO tid for 7–10 days to ensure streptococcal coverage [4]
  • doxycycline 100 mg PO bid (avoid in pregnancy/young children) may be combined with amoxicillin-clavulanate for streptococcal coverage [4]
• Severe infection, systemic toxicity, or failed oral therapy (admission/IV)
  • ampicillin-sulbactam 3 g IV q6h or cefazolin 1–2 g IV q8h [4]
  • Add vancomycin IV if MRSA is a concern or local prevalence is high [4]
  • Broaden gram-negative coverage (e.g., piperacillin-tazobactam) for healthcare-exposed or immunocompromised patients [4]
• Adjuncts
  • Warm compresses 10–15 minutes, 3–4 times daily
  • Topical broad-spectrum antibiotic drops (e.g., moxifloxacin 0.5% 1 drop qid) may reduce conjunctival bacterial load; adjunctive/off-label for dacryocystitis
  • Analgesics (acetaminophen or NSAIDs as appropriate)
• Infants and children
  • Well-appearing child with mild infection: amoxicillin-clavulanate 25–45 mg/kg/day PO divided bid for 7–10 days [3,5]
  • Neonates, toxic appearance, or failure of oral therapy: hospitalize; IV ampicillin-sulbactam 100–200 mg/kg/day (ampicillin component) divided q6h or cefazolin 25–50 mg/kg/day divided q8h; obtain blood cultures [3,5]
  • Avoid doxycycline in children <8 years; use TMP-SMX cautiously in infants and in pregnancy

Acute abscess: consider incision and drainage of the lacrimal sac abscess with culture if pointing or skin necrosis is imminent, combined with systemic antibiotics.

Definitive management: After infection calms (typically 1–2 weeks), evaluate and treat underlying obstruction to prevent recurrence.

Procedural and surgical management

• Dacryocystorhinostomy (DCR): Creates a direct drainage tract from the lacrimal sac into the nasal cavity
  • Approaches: external DCR or endoscopic endonasal DCR; similar success rates in experienced hands (approximately 85–95%) [6,7]
  • Indications: recurrent acute or chronic dacryocystitis with obstructed NLD; failed conservative therapy
  • Silicone stent placement is commonly used to maintain patency during healing
  • Perioperative antibiotics per surgeon preference and culture history
  • Coding (professionals): external DCR (CPT 68720); endoscopic DCR (CPT 31239)
• Probing/irrigation of the nasolacrimal system
  • Infants with persistent CNLDO and recurrent infection: perform probing after infection resolves; timing often at 6–12 months if not spontaneously resolved or earlier if recurrent dacryocystitis or dacryocele with respiratory compromise [3,5]
  • Coding (professionals): probing of nasolacrimal duct (CPT 68810)
• Dacryocele (neonate)
  • Start systemic antibiotics for infection; if intranasal cyst causes airway obstruction or fails conservative care, endoscopic marsupialization of the intranasal component is indicated [3]

Avoid intraocular surgery (e.g., cataract extraction) in the presence of active dacryocystitis due to endophthalmitis risk.

Special populations

• Pregnancy/lactation: amoxicillin-clavulanate and cephalexin are preferred; avoid doxycycline; TMP-SMX is generally avoided in late pregnancy and in neonates. Coordinate with obstetrics when IV therapy is needed.
• Immunocompromised: consider broader empiric coverage and early imaging; evaluate for fungal or atypical organisms; culture-directed therapy is important.
• Older adults: higher prevalence of PANDO; plan for definitive DCR after infection control.

Prognosis

With prompt systemic antibiotics and appropriate surgical correction of obstruction, prognosis is good. Recurrent infection is common if obstruction is not addressed. Neonatal cases respond well to antibiotics and timely probing; however, untreated cases risk sepsis and orbital complications. DCR provides durable symptom relief in most patients, with high anatomical and functional success rates in experienced centers [6,7].

Prevention and Patient Counseling

• Recognize and treat episodes early to prevent abscess and spread.
• Do not attempt forceful sac massage during acute infection; gentle warm compresses are acceptable.
• After resolution, definitive treatment of obstruction (often DCR) prevents recurrence.
• For congenital obstruction without acute infection, caregivers may use Crigler lacrimal sac massage technique as instructed by a clinician; escalate to probing if persistent or recurrent infections occur [3,5].
• Maintain nasal/sinus health; manage allergic rhinitis and chronic rhinosinusitis where relevant.

When to Seek Immediate Care

• Sudden vision loss, double vision, or pain with eye movements
• Bulging of the eye, inability to move the eye normally, or severe headache/fever
• Rapidly spreading redness or swelling around the eye
• A tender, enlarging, fluctuant mass at the inner corner of the eye
• In infants: fever, poor feeding, lethargy, or a bluish mass at the inner corner with breathing trouble
• Any worsening despite 24–48 hours of antibiotics

References

1. Ali MJ. Dacryocystitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 30085556.
2. American Academy of Ophthalmology EyeWiki. Dacryocystitis. https://eyewiki.aao.org/Dacryocystitis. Accessed July 24, 2026.
3. American Association for Pediatric Ophthalmology and Strabismus (AAPOS). Nasolacrimal Duct Obstruction. https://aapos.org/glossary/nasolacrimal-duct-obstruction. Accessed July 24, 2026.
4. Brook I. Microbiology and management of dacryocystitis in adults. Int Ophthalmol Clin. 2007;47(1):57-69. doi:10.1097/IIO.0b013e31802b5b27.
5. MedlinePlus. Blocked Tear Duct in Babies. https://medlineplus.gov/ency/article/001010.htm. Accessed July 24, 2026.
6. Hii BW, McNab AA. Endoscopic and external dacryocystorhinostomy: a systematic review. Clin Otolaryngol. 2012;37(6):452-457. doi:10.1111/coa.12005.
7. Feng YF, Cai JQ, Zhang JY. A meta-analysis of primary endoscopic versus external dacryocystorhinostomy. BMC Ophthalmol. 2013;13:50. doi:10.1186/1471-2415-13-50.

Disclaimer: This article is for informational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified eye care professional about your specific condition. If you have sudden vision loss, severe eye pain, or an eye injury, seek emergency care immediately.